FDA conducting safety review of gonadotropin-releasing hormone (GnRH) agonists - ONA
Links shared publicly online about this topic.
- 1,195total visits
FDA conducting safety review of gonadotropin-releasing hormone (GnRH) agonists - ONA
View full resource at oncologynurseadvisor.com
Tags: Heart, Hormone, Diabetes, Infertility, Healthcare, FDA, Safety
Most Recently Shared on May 3, 2010 at 8:48 pm By:
FDA conducting safety review of gonadotropin-releasing hormone (GnRH) agonists http://goo.gl/fb/lG64E
GnRH Agonist Safety Is Under Review - Renal and Urology News
renalandurologynews.com — “The FDA is conducting a safety review of gonadotropin-releasing hormone (GnRH) agonists, a class of drugs used primarily as a treatment for prostate cancer.” View full resource at renalandurologynews.com
Most Recently Shared on June 15, 2010 at 7:38 am By:
Renal Urology News Health News, Nephrology, Urology, and Medical Publisher
GnRH Agonist Safety Is Under Review: The FDA is conducting a safety review of gonadotropin-releasing hormone (GnRH... http://bit.ly/cu6mf6
FDA Drug Safety Communication: Ongoing Safety Review of GnRH Agonists and Possible Increased Risk of Diabetes and Certain Cardiovascular Diseases - Drugs.com MedNews
drugs.com — “05-03-2010 The U.S. Food and Drug Administration (FDA) is evaluating whether Gonadotropin-Releasing Hormone (GnRH) Agonists may increase the risk of diabetes an” View full resource at drugs.com
Most Recently Shared on May 4, 2010 at 11:02 pm By:
FDA: Ongoing Safety Review of GnRH Agonists - http://bit.ly/bDyEi7
Medical News: FDA Scrutiny of GnRH Agonists Continues - in Product Alert, Prescriptions from MedPage Today
medpagetoday.com — “WASHINGTON -- Although an FDA safety review of the gonadotropin-releasing hormone (GnRH) agonist class of prostate cancer drugs has not yet been concluded, the agency is advising that the risks of the” View full resource at medpagetoday.com
Most Recently Shared on May 3, 2010 at 10:51 pm By:
FDA Scrutiny of GnRH Agonists Continues http://bit.ly/9iq9fL
FDA conducting safety review of gonadotropin-releasing hormone (GnRH) agonists - MPR
empr.com — “The FDA has notified healthcare professionals and patients of a preliminary and ongoing review which suggests an increase in the risk of diabetes and certain cardiovascular diseases in men treated with gonadotropin-releasing hormone (GnRH) agonists for the treatment of prostate cancer.” View full resource at empr.com
Most Recently Shared on May 3, 2010 at 9:09 pm By:
MPR News: FDA conducting safety review of gonadotropin-releasing hormone (GnRH) agonists: The FDA has notified hea... http://bit.ly/98AHkZ
FDA Conducting Safety Review of Commonly Used Prostate Cancer Drugs
fda.gov — “Gonadotropin-Releasing Hormone (GnRH) agonists, a class of medications primarily used to treat men with prostate cancer, have been associated with a small increased risk for diabetes, heart attack, stroke, and sudden death in men treated with one of the medications, according to a preliminary and ongoing analysis of several studies by the U.S. Food and Drug Administration.” View full resource at fda.gov
Most Recently Shared on May 3, 2010 at 3:13 pm By:
FDA Conducting Safety Review of Commonly Used Prostate Cancer Drugs http://bit.ly/dcnL1Q
Advertisement
